<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04159311</url>
  </required_header>
  <id_info>
    <org_study_id>CParisBercy</org_study_id>
    <nct_id>NCT04159311</nct_id>
  </id_info>
  <brief_title>Osteopathy on IBS Symptoms in Patients With Ulcerative Colitis in Remission</brief_title>
  <acronym>OSTEOMIC</acronym>
  <official_title>Impact of Osteopathy on IBS-like Symptoms Associated With Ulcerative Colitis in Patients in Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique Paris-Bercy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinique Paris-Bercy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type : interventional, randomized single blind study Aim : to evaluate 3 sessions of&#xD;
      osteopathy on IBS-like symptoms associated with ulcerative colitis in remission Number of&#xD;
      patients : 50 (randomization 1:1) Duration of the inclusion period : 2 years Primary&#xD;
      end-point : Irritable Bowel Syndrome Severity Scoring System (IBS SSS) at 3 months&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteopathy has been shown to be effective in IBS patients in few studies and to improse&#xD;
      IBS-like symptoms in a short series of Crohn patients. IBS-like symptoms are frequent in&#xD;
      patients with ulcerative colitis in remission (about 20 %).&#xD;
&#xD;
      The aim of this interventional, randomized single blind study is to evaluate the impact of 3&#xD;
      sessions of osteopathy on Irritable Bowel Syndrome symptoms in 50 patients (randomisation&#xD;
      1:1) with ulcerative colitis in remission (defined by fecal calprotectin &lt; 200 µg/g).&#xD;
&#xD;
      The two group of patients will have 4 sessions of osteopathy (M0, M1, M2, M3). The &quot;treated&#xD;
      group&quot; will have 3 sessions of osteopathy testing followed by osteopathy treatment (M0, M1,&#xD;
      M2) and a final testing session at M3. The &quot;untreated group&quot; will have 4 sessions of only&#xD;
      testing osteopathy (M0, M1, M2, M3).&#xD;
&#xD;
      Primary end-points : Irritable Bowel Syndrome Severity Scoring System (IBS SSS) at 3 months&#xD;
      (M3) Secondary end-points : Inflammatory Bowel Disease Questionnaire ol, Functional&#xD;
      Assessment of Chronic Illness Therapy-Fatigue at M3, evaluation of osteopathic dysfunctions&#xD;
      between M0 and M3, questionnaire for use of medication for IBS between M0 and M3&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 14, 2019</start_date>
  <completion_date type="Anticipated">November 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the score change of Irritable Bowel Syndrome Severity Scoring System (IBS SSS)</measure>
    <time_frame>Month 1, Month 2, Month 3, Month 4</time_frame>
    <description>index of severity of Irritable Bowel Syndrome symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IBDQol : Inflammatory Bowel Disease Questionnaire</measure>
    <time_frame>Month 1, Month 2, Month 3, Month 4</time_frame>
    <description>Index of quality of life dedicated to Inflammatory Disease Bowel patients : the score is high, better the quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FACIT-F : Functional Assessment of Chronic Illness Therapy-Fatigue</measure>
    <time_frame>Month 1, Month 2, Month 3, Month 4</time_frame>
    <description>Validated fatigue score with question about quality of life 45/5000&#xD;
if the score is high, the patient is tired</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of osteopathic dysfunctions</measure>
    <time_frame>Month 1, Month 2, Month 3, Month 4</time_frame>
    <description>it will be interesting to see if patients with remission-prone RCH have similar osteopathic dysfunctions at the beginning of the study, and then if the management during the study influences or not these osteopathic dysfunctions.&#xD;
Osteopathic dysfunction is an alteration of the mobility, viscoelasticity or texture of somatic system components. It is accompanied or not by a painful sensibility.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire for use of medication for Irritable Bowel Syndrome</measure>
    <time_frame>Month 1, Month 2, Month 3, Month 4</time_frame>
    <description>if treatment modification, dose reduction or change in treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Treated group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The &quot;treated group&quot; will have 3 sessions of osteopathy testing followed by osteopathy treatment (M0, M1, M2) and a final testing session at M3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The &quot;untreated group&quot; will have 4 sessions of only testing osteopathy (M0, M1, M2, M3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Osteopathy</intervention_name>
    <description>testing osteopathy Vs Treating osteopathy</description>
    <arm_group_label>Treated group</arm_group_label>
    <arm_group_label>Untreated group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Age between 18 and 90&#xD;
&#xD;
          -  Patient with ulcerative colitis (whatever the Montreal grade, E1, E2 or E3) In&#xD;
             clinical remission for at least 3 months and with fecal calprotectin &lt; 200 µg/g&#xD;
&#xD;
          -  No modification of Ulcerative Colitis treatment for at least 3 months&#xD;
&#xD;
          -  Patient with IBS-liked symptoms defined as in Rome IV classification for Irritable&#xD;
             Bowel Syndrome&#xD;
&#xD;
          -  Patient with Irritable Bowel Syndrome Severity Scoring System &gt; 75 at screening&#xD;
&#xD;
          -  Patient affiliated to the French Social Security regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal&#xD;
&#xD;
          -  Patient &lt; 18 yoa&#xD;
&#xD;
          -  Patient with colonic or ileal stenosis&#xD;
&#xD;
          -  Patient diagnosed as undetermined colitis&#xD;
&#xD;
          -  Patient not in remission for Ulcerative Colitis as defined by an endoscopic Mayo score&#xD;
             &gt; 1 within the 3 months preceding the inclusion and/or fecal calprotectin &gt; 200 µg/g&#xD;
             at inclusion&#xD;
&#xD;
          -  Osteopathy session(s) within 1 month before inclusion&#xD;
&#xD;
          -  Patient with Inflammatory rheumatic disorders (ankylosing spondylitis, psoriatic&#xD;
             arthritis, rheumatoid arthritis)&#xD;
&#xD;
          -  Patient with Irritable Bowel Syndrome Severity Scoring System &lt;75 at screening&#xD;
&#xD;
          -  Patient above 18 yoa with law guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maryan Cavicchi, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Clinique Paris-Bercy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bouchra Benkessou, SC</last_name>
    <phone>0033 764486016</phone>
    <email>b.benkessou@cliniques-bltparis.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maryan Cavicchi, MD, PhD</last_name>
    <phone>0033 0662346680</phone>
    <email>maryan.cavicchi@dbmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Paris Bercy</name>
      <address>
        <city>Charenton Le Pont</city>
        <zip>94220</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BOUCHRA BENKESSOU, SC</last_name>
      <phone>0143967823</phone>
      <email>b.benkessou@clinique-bercy.fr</email>
    </contact>
    <contact_backup>
      <last_name>CLEO COURRENT</last_name>
      <email>cleo.courrent@yahoo.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 17, 2019</study_first_submitted>
  <study_first_submitted_qc>November 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>December 30, 2019</last_update_submitted>
  <last_update_submitted_qc>December 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

